Skip to content

Ketamine research published in 2025

Page 27 of 39: studies 521 to 540 of 780, newest first. Back to the ketamine overview

Studies

Ketamine Versus Electroconvulsive Therapy for the Treatment of Depression: A Guide for Clinicians.

FOCUS: The Journal of Lifelong Learning in Psychiatry April 1, 2025 Sophie I Elliott, Rachel B. Katz, Robert Ostroff et al. 2 citations

The effective treatment of major depressive disorder remains one of the biggest public health challenges globally. For moderate to severe cases, pharmacotherapy often falls short, leading to treatment-resistant depression. Electroconvulsive therapy (ECT) has generally been considered the gold standard for severe cases of treatment-resistant depression. However, emerging evidence suggests that...

Investigating the Mechanisms of Esketamine in Treating Propofol-Induced Cognitive Impairment in Elderly Rats.

Discovery medicine April 1, 2025 Jieru Zhang, Guofeng Xu, Xiaoli Wang et al.

Common cognitive impairment in the elderly may be aggravated by the anesthetic propofol, whereas the mammalian target of rapamycin protein (mTOR)-brain-derived neurotrophic factor (BDNF) pathway and autophagy regulation play a key role in neuroprotection. In this study, we investigated whether esketamine can improve propofol-induced cognitive impairment in aged rats by affecting these...

DOI: 10.24976/Discov.Med.202537195.60 (opens in new tab) Full text (opens in new tab) Esketamine Mtor-bdnf pathway Neuronal autophagy Postoperative cognitive dysfunction +6

Ketamine-Assisted Psychotherapy for Treatment of Co-occurring Borderline Personality Disorder and Depression: A Case Study.

Journal of personality disorders April 1, 2025 Albert Yeung, Michael Alpert, David Mischoulon 3 citations

Borderline personality disorder (BPD) is a mental health condition characterized by a pervasive pattern of impulsivity, affective dysregulation, and cognitive-perceptual symptoms. Treatment of BPD remains a significant challenge to mental health clinicians. People who suffer from BPD frequently have comorbid psychiatric disorders, which makes treatment more complex. This case study describes a...

The Lethal Combination of Pregabalin With Other Recreational Drugs.

Cureus April 1, 2025 Alison Muñoz, Marai Roque, Marco Valladares et al.

This case presents a 33-year-old male with a four-day history of worsening altered mental status and rhabdomyolysis. He experienced delusions, restlessness, and visual hallucinations, exacerbated by prolonged multidrug abuse, including over-the-counter pregabalin (Lyrica) for pain relief and recreational ketamine. Despite an initially incomplete history and unclear etiology, the patient was...

Inhibition of autophagy by esketamine attenuates hypoxia/reoxygenation injury in cardiomyocytes via inhibition of Ca2+/CaMKKβ/AMPK/mTOR pathway by down-regulation of transient receptor potential vanilloid 1 expression.

Journal of physiology and pharmacology : an official journal of the Polish Physiological Society April 1, 2025 Y Zhang, Q M Lu, H C Hu et al.

This research sought to determine the influence of esketamine (ESK) on hypoxia/reoxygenation (H/R) injury in cardiomyocytes by blocking autophagy via the transient receptor potential vanilloid type 1 (TRPV1)/ Ca2+/ calmodulin-dependent protein kinase β (CaMKKβ)/ adenosine monophosphate (AMP)-activated protein kinase (AMPK)/ mammalian target of rapamycin (mTOR) pathway. H9c2 cardiomyocytes were...

Neuropharmacology of Ketamine and Its Use in the Treatment of Major Depressive Disorder: A Review.

Cureus April 1, 2025 Zach Papadopoulos 1 citation

Depression is a common yet potentially debilitating mood disorder with complex neurobiological underpinnings, including deficiencies in monoaminergic and glutamatergic signaling, overactivity of the lateral habenula, and dysregulation of brain-derived neurotrophic factor (BDNF) signaling. Ketamine has emerged as a mechanistically novel, effective, and rapidly acting antidepressant. Ketamine's...

Connectome harmonic decomposition tracks the presence of disconnected consciousness during ketamine-induced unresponsiveness.

British Journal of Anaesthesia April 1, 2025 Milan Van Maldegem, Jakub Vohryzek, Selen Atasoy et al. 3 citations

Ketamine, in doses suitable to induce anaesthesia in humans, gives rise to a unique state of unresponsiveness accompanied by vivid experiences and sensations, making it possible to disentangle the correlated but distinct concepts of conscious awareness and behavioural responsiveness. This distinction is often overlooked in the study of consciousness. The mathematical framework of connectome...

DOI: 10.1016/j.bja.2024.12.036 (opens in new tab) Full text (opens in new tab) Consciousness research Psychedelic medicine Brain imaging Ketamine effects +6

Comparative Efficacy and Functional Outcomes of Psychedelic-Assisted Therapies in Treatment-Resistant Depression: A Systematic Review of Recent Clinical Trials.

Cureus April 1, 2025 Ciara Mimms, Kassandra Sotelo, Abdul Saboor Khaliq 1 citation

This systematic review explores the comparative efficacy and functional outcomes of psychedelic-assisted therapies in the management of treatment-resistant depression (TRD). Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a comprehensive literature search was conducted across PubMed, Scopus, and Web of Science for randomized controlled...

Repeated administration of a subanesthetic dose of ketamine results in impaired motor and cognitive behavior and differential expression of hippocampal P2X1 and P2X7 receptors in adult mice.

Behavioural Brain Research March 28, 2025 Teresa Belem Mares-Barbosa, Ares Orlando Cuellar-Santoyo, Victor Manuel Ruiz-Rodríguez et al. 3 citations

Ketamine hydrochloride serves multiple purposes, including its use as a general anesthetic, treatment for depression, and recreational drug. In studies involving rodents, ketamine is utilized as a model for schizophrenia. However, it is unclear whether age affects the behavioral response induced by repeated ketamine administration and if it modifies the expression levels of N-methyl-D-aspartate...

Prophylactic Ketamine: Current Knowledge and Future Directions.

Biological Psychiatry March 28, 2025 Astrid M Cardona-Acosta, Lyonna F Parise, Carlos A. Bolaños-Guzmán et al. 2 citations

The prevalence of stress-induced disorders, including depression, anxiety, posttraumatic stress disorder, and postpartum depression, has been increasing, while current treatment approaches are limited. As a result, researchers are exploring alternative treatments that include ketamine as a prophylactic against these disorders. This review provides an overview of the current knowledge on the use...

DOI: 10.1016/j.biopsych.2025.03.015 (opens in new tab) Full text (opens in new tab) Neuroprotective drugs Prophylactic treatment Stress resilience Stress-induced psychiatric disorders +5

Innovative approaches in the treatment-resistant depression: exploring different therapeutic pathways.

GeroScience March 25, 2025 Anna Łysik, Katarzyna Logoń, Aleksandra Szczygieł et al. 8 citations

Treatment-resistant depression (TRD) remains a vital challenge in psychiatry, affecting a significant number of patients with major depressive disorder. Current pharmacological approaches often do not provide sufficient therapeutic results, prompting the need for innovative treatments. This review summarizes recent advances in TRD management, including non-pharmacological therapies such as...

Qualitative analysis of a patient's experience of ketamine-assisted psychotherapy for substance use disorder: Empirical synergies with twelve-step programs

Psychiatry Research Case Reports March 24, 2025 Dan Petrovitch, Jacob Spinks, H.J. Yoo et al. 3 citations

Ketamine has demonstrated early promise for treating substance use disorder (SUD). Despite the emerging evidence for ketamine-based approaches for SUD, little has been published on the integration of ketamine-assisted psychotherapy (KAP) with existing pharmacologic, psychosocial, and peer-support approaches to treatment and recovery, including 12-step programs. Here, we present the case of a...

DOI: 10.1016/j.psycr.2025.100259 (opens in new tab) Ketamine Psychotherapist Substance use Empirical research

Monoamine neurotransmitter-related gene-based genome-wide association study of low-dose ketamine in patients with treatment-resistant depression.

Journal of Psychopharmacology March 24, 2025 Chung-Feng Kao, Shih-Jen Tsai, Tung-Ping Su et al. 1 citation

Low-dose ketamine is an N-methyl-D-aspartate receptor antagonist that exerts an antidepressant effect on patients with treatment-resistant depression (TRD). This antidepressant effect may extend beyond the glutamatergic hypothesis. Nevertheless, the roles of genes encoding other monoamine neurotransmitters (i.e., serotonin and dopamine) in the neuromechanism of low-dose ketamine remain unknown....

DOI: 10.1177/02698811251326939 (opens in new tab) Full text (opens in new tab) Treatment-resistant depression Neurotransmitter studies Psychiatric genomics Antidepressant mechanisms +4

Oral Ketamine for the Treatment of Depression: A randomized controlled trial and meta-analysis

medRxiv Preprint Server March 21, 2025 Leo R. Silberbauer, Benjamin Eggerstorfer, Paul Michenthaler et al. 1 citation preprint

Background Ketamine represents a significant advancement in antidepressant therapy, but the commonly used intravenous and intranasal application routes currently limit its availability beyond specialized centers. By contrast, oral ketamine treatment might constitute an alternative that is easy to administer with established safety and efficacy for patients with chronic and severe pain at home.

DOI: 10.1101/2025.03.21.25324252 (opens in new tab) Full text (opens in new tab) Depression treatment Mental health management Mood disorder therapy Antidepressant care +18

[Esketamine Alleviates Postoperative Depressive Symptoms in Frail Elderly Patients Undergoing Thoracoscopic Radical Resection of Lung Cancer: A Randomized Double-Blind Controlled Trial].

Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition March 20, 2025 Congli Zhang, Yan Yan, Junjie Ma et al. 1 citation

To investigate the effect of esketamine on postoperative depression in frail elderly patients undergoing thoracoscopic radical resection of lung cancer. A total of 88 frail elderly patients undergoing elective thoracoscopic radical resection of lung cancer were assigned randomly (using a randomization table) and in a double-blind way (blinding applies to both researchers and patients) to an...

DOI: 10.12182/20250360202 (opens in new tab) Full text (opens in new tab) Frail elderly patients Postoperative depressive state Thoracoscopy Esketamine: esketamine +8

N-Acetylcysteine Mitigates Ketamine Neurotoxicity in Young Rats by Modulating ROS-Mediated Pyroptosis and Ferroptosis.

Molecular Neurobiology March 20, 2025 Hui Bai, Hui Chen, Shan Du et al. 4 citations

Ketamine, an N-methyl-D-aspartate receptor antagonist with anesthetic and analgesic properties, is extensively utilized for the induction and maintenance of pediatric perioperative anesthesia. Increasing evidence suggests that prolonged exposure to ketamine may induce neurotoxicity in developing animals, adversely affecting their long-term cognitive function. N-acetylcysteine (NAC) is an...

DOI: 10.1007/s12035-025-04860-2 (opens in new tab) Full text (opens in new tab) Ketamine Pediatric anesthesia Oxidative stress Brain development +7

Ketamine as adjuvant treatment in eating disorders: an exploratory study of a case series and retrospective analysis.

Journal of Eating Disorders March 17, 2025 Paula J Escobedo-Aedo, Chris Serrand, Sarah Kabani et al. 4 citations

Eating disorders (EDs) significantly impair physical health and psychosocial functioning. Few effective therapeutic approaches exist for EDs, particularly in Anorexia Nervosa (AN). The use of ketamine, already characterized as a noncompetitive NMDA antagonist anesthetic in depression and suicidal ideations, could be an innovative adjuvant treatment for the AN spectrum. We describe a case series...

DOI: 10.1186/s40337-025-01232-y (opens in new tab) Full text (opens in new tab) Ketamine therapy Eating disorder treatment Mental health research Anorexia treatment +5

Ketamine and Hydroxynorketamine as Novel Pharmacotherapies for the Treatment of Opioid Use Disorders.

Biological Psychiatry March 15, 2025 Anna Onisiforou, Andria Michael, Markos Apostolakis et al. 14 citations

Opioid use disorder (OUD) has reached epidemic proportions, with many countries facing high levels of opioid use and related fatalities. Although currently prescribed medications for OUD are considered lifesaving, they inadequately address negative affect and cognitive impairment, resulting in high relapse rates to nonmedical opioid use even years after drug cessation (protracted abstinence)....

DOI: 10.1016/j.biopsych.2024.09.008 (opens in new tab) Full text (opens in new tab) Hydroxynorketamine Opioid crisis Opioid use disorders Relapse +4

Associations between hypothalamic-pituitary-adrenal (HPA) axis hormone levels, major depression features and antidepressant effects of ketamine.

Journal of Affective Disorders March 15, 2025 Polymnia Georgiou, Cristan A Farmer, Gustavo C Medeiros et al. 24 citations

Subanesthetic doses of (R,S)-ketamine (ketamine) have demonstrated rapid and robust antidepressant effects in individuals with depression. However, individual variability in response to ketamine exists, and current biomarkers of ketamine treatment response are not entirely understood. Preclinical evidence suggests a link between hypothalamic-pituitary-adrenal (HPA) axis activation, a...

DOI: 10.1016/j.jad.2024.12.036 (opens in new tab) Full text (opens in new tab) Depression Adrenocorticotropic hormone Corticotropin releasing factor Cortisol +4

Trends and characteristics in ketamine use among US adults with and without depression, 2015-2022.

Journal of Affective Disorders March 15, 2025 Kevin H. Yang, Wayne Kepner, Charles M Cleland et al. 19 citations

Ketamine's potential for treating depression has drawn increased clinical interest in recent years. However, despite growing therapeutic use, recreational use among individuals with depression remain underexplored. We analyzed data from the 2015-2022 National Survey on Drug Use and Health focusing on adults in the US. Trends in past-year ketamine use, overall and by depression status, were...

DOI: 10.1016/j.jad.2024.12.108 (opens in new tab) Full text (opens in new tab) Depression Nationally representative samples Ketamine-use-trends Mental-health-epidemiology +2